Biostar Pharmaceuticals Delays Board Meeting to 30 March for Completion of FY2025 Results

Bulletin Express03-24

Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharmaceuticals) announced that its board of directors has rescheduled the upcoming meeting originally set for 25 March 2026. The session, which will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider any proposed final dividend, will now take place on 30 March 2026.

The postponement was attributed to the additional time required for the company and its auditor to complete the review and finalisation of the FY2025 financial statements.

The board composition remains unchanged, comprising six executive and non-executive directors and three independent non-executive directors, with Dr. Tang Li serving as chairman and executive director.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151953506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151953506","market":"hk","top_or_hot":-1,"title":"Biostar Pharmaceuticals Delays Board Meeting to 30 March for Completion of FY2025 Results","media":"Bulletin Express","content":"<p>Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharmaceuticals) announced that its board of directors has rescheduled the upcoming meeting originally set for 25 March 2026. The session, which will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider any proposed final dividend, will now take place on 30 March 2026.</p>\n<p>The postponement was attributed to the additional time required for the company and its auditor to complete the review and finalisation of the FY2025 financial statements.</p>\n<p>The board composition remains unchanged, comprising six executive and non-executive directors and three independent non-executive directors, with Dr. Tang Li serving as chairman and executive director.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biostar Pharmaceuticals Delays Board Meeting to 30 March for Completion of FY2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiostar Pharmaceuticals Delays Board Meeting to 30 March for Completion of FY2025 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-24 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharmaceuticals) announced that its board of directors has rescheduled the upcoming meeting originally set for 25 March 2026. The session, which will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider any proposed final dividend, will now take place on 30 March 2026.</p>\n<p>The postponement was attributed to the additional time required for the company and its auditor to complete the review and finalisation of the FY2025 financial statements.</p>\n<p>The board composition remains unchanged, comprising six executive and non-executive directors and three independent non-executive directors, with Dr. Tang Li serving as chairman and executive director.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02563","symbol_name":"华昊中天医药-B","start_time":0,"source_url":"","article_id":"1151953506","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151953506","pubTimestamp":1774360861,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharmaceuticals) announced that its board of directors has rescheduled the upcoming meeting originally set for 25 March 2026. The session, which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02563":"华昊中天医药-B"},"translate_title":"Biostar Pharmaceuticals将董事会会议推迟至3月30日以完成2025财年业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":1},"content_text":"Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharmaceuticals) announced that its board of directors has rescheduled the upcoming meeting originally set for 25 March 2026. The session, which will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider any proposed final dividend, will now take place on 30 March 2026.\nThe postponement was attributed to the additional time required for the company and its auditor to complete the review and finalisation of the FY2025 financial statements.\nThe board composition remains unchanged, comprising six executive and non-executive directors and three independent non-executive directors, with Dr. Tang Li serving as chairman and executive director.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151953506","isCrawlerRequest":true}